Eye Health

The pipeline for eye health is full of potential therapies. Here's a look at 4 that may be available in the near future.

The price of the biosimilar may also be persuasive for patients.

The drug is a potential new therapy for dry eye disease with a novel mechanism of action.

The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.

The CLEAR Act would clarify the FDA’s authority to regulate products, including eye drops, after a court decision created unnecessary confusion and turmoil.

A team of investigators has found that there is a bidirectional association between chronic kidney disease and glaucoma.

As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.

Research highlights link between impaired vision and mental health in children.

Eyelid ptosis can be treated with α-adrenergic eye drops.

The biosimilar has a list price 40% less than its reference product.

A new report from the CDC that examined 20-year trends in vision impairment among patients with diabetes, which suggests the rate of decline in vision impairment began to plateau in 2012 and may be on the rise in recent years.

The Focus on Diabetes program will be sharing resources through the end of the month.

Researchers may have identified a potential solution.

Asthma may increase a person’s risk of developing dry eye disease.

Medications like inhalers and nasal sprays can be challenging for patients to administer correctly.

A University of Houston study found that minorities have fewer eye exams, higher instances of disease.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

A new treatment option may increase basal tear production in patients.

Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients with dry eye.